跳至主要内容
临床试验/CTRI/2024/06/069345
CTRI/2024/06/069345尚未招募Phase 3 4

Efficacy of Tazarotene 0.05 percent gel vs Adapalene 0.1 percent gel in treatment of acne vulgaris A randomised case controlled trial

Dr Sharwari Jaiswal1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年7月17日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
发起方
入组人数
150
试验地点
1
主要终点
To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, and the side effects that arise with the usage of 0.05% tazarotene and 0.1% adapalene.

研究概览

简要总结

Acne is an extremely common skin condition, which has a major social and psychological impact  on young  patients [3]. Retinoids have been a mainstay of anti-acne therapy. Older generation agents are slowly replaced by newer generation ones like tazarotene and adapalene as they exhibit lower toxicologic risk and less side effects and they effectively reduce the comedones and inflammatory lesions. Unlike Tretinoin, these are newer agents are specific for a subset of retinoic acid receptors exhibiting lower toxicologic risk and producing fewer side effects.This study tthrows light on effectiveness of topical Adapalene gel- 0.1% and Tazarotene gel-0.05% in order to find out a suitable option with lesser side effects for acne patients.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
12.00 Year(s) 至 35.00 Year(s)(—)
性别
All

入选标准

  • Patients irrespective of gender.
  • Patients with acne grade: I, II, III.

排除标准

  • 1.History of hypersensitivity or allergic reaction to retinoids 2.Patients with a history of photosensitivity.
  • 3.Females who are pregnant, lactating mothers and married women planning for pregnancy.
  • 4.Patient with photo aggravated disorders.

结局指标

主要结局

To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, and the side effects that arise with the usage of 0.05% tazarotene and 0.1% adapalene.

时间窗: 1 year 2 months

次要结局

  • treatment wherein oral medication need not be given or are contraindicated.(8 weeks)
  • Total clearance of lesions, improvement in numbers of counts of comedones, papules, pustules, & nodules, improvement in global acne scoring, side effects i.e. dryness, erythema, itching, & flare-up of acne will be studied. To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, & the side effects that arise with the usage of 0.05% tazarotene & 0.1% adapalene.(12 weeks)

研究者

发起方
Dr Sharwari Jaiswal
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验